These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Beyond the laboratory: clinical implications for statin pleiotropy. Halcox JP; Deanfield JE Circulation; 2004 Jun; 109(21 Suppl 1):II42-8. PubMed ID: 15173062 [TBL] [Abstract][Full Text] [Related]
4. Optimal medical management of peripheral arterial disease. Rice TW; Lumsden AB Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725 [TBL] [Abstract][Full Text] [Related]
5. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Mora S; Ridker PM Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935 [TBL] [Abstract][Full Text] [Related]
6. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials? Ray KK; Cannon CP; Ganz P Am J Cardiol; 2006 Dec; 98(11A):18P-25P. PubMed ID: 17126675 [TBL] [Abstract][Full Text] [Related]
7. The role of statins in reversing atherosclerosis: what the latest regression studies show. Grines CL J Interv Cardiol; 2006 Feb; 19(1):3-9. PubMed ID: 16483333 [TBL] [Abstract][Full Text] [Related]
8. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)? Sever PS Am J Med; 2005 Dec; 118 Suppl 12A():3-9. PubMed ID: 16356801 [TBL] [Abstract][Full Text] [Related]
9. Altering the pathophysiology of atherosclerosis: the multidimensional role of statins. Clearfield MB J Am Osteopath Assoc; 2010 Apr; 110(4 Suppl 4):S2-6. PubMed ID: 20453192 [TBL] [Abstract][Full Text] [Related]
10. Renin-angiotensin system antagonism and lipid-lowering therapy in cardiovascular risk management. Chiong JR; Miller AB J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):96-102. PubMed ID: 12228849 [TBL] [Abstract][Full Text] [Related]
11. Statins and LDL-cholesterol lowering: an overview. Stroes E Curr Med Res Opin; 2005; 21 Suppl 6():S9-16. PubMed ID: 16138936 [TBL] [Abstract][Full Text] [Related]
12. Management of hyperlipidemia in older adults. Alexander KP; Blazing MA; Rosenson RS; Hazard E; Aronow WS; Smith SC; Ohman EM J Cardiovasc Pharmacol Ther; 2009 Mar; 14(1):49-58. PubMed ID: 19124599 [TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering effect of preoperative statin therapy on postoperative major adverse cardiac events after coronary artery bypass surgery. Thielmann M; Neuhäuser M; Marr A; Jaeger BR; Wendt D; Schuetze B; Kamler M; Massoudy P; Erbel R; Jakob H J Thorac Cardiovasc Surg; 2007 Nov; 134(5):1143-9. PubMed ID: 17976441 [TBL] [Abstract][Full Text] [Related]
14. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Schönbeck U; Libby P Circulation; 2004 Jun; 109(21 Suppl 1):II18-26. PubMed ID: 15173059 [TBL] [Abstract][Full Text] [Related]
15. Lipids in health and disease. Shepherd J Biochem Soc Trans; 2004 Dec; 32(Pt 6):1051-6. PubMed ID: 15506961 [TBL] [Abstract][Full Text] [Related]
16. Potential vascular benefits of statins. Kinlay S Am J Med; 2005 Dec; 118 Suppl 12A():62-7. PubMed ID: 16356810 [TBL] [Abstract][Full Text] [Related]
17. Lipid abnormalities in the nephrotic syndrome: the therapeutic role of statins. Wheeler DC J Nephrol; 2001; 14 Suppl 4():S70-5. PubMed ID: 11798150 [TBL] [Abstract][Full Text] [Related]